Literature DB >> 16957514

Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.

Daniel L Worthley1, Alicia Smith, Peter A Bampton, Stephen R Cole, Graeme P Young.   

Abstract

OBJECTIVES: Population-based colorectal cancer screening by fecal occult blood testing reduces cancer-specific mortality. Current guidelines recommend this strategy for average risk individuals. This study investigated the prevalence of higher-than-average risk characteristics, and rate of prior colonoscopy, in participants in fecal occult blood test screening programs.
METHODS: Randomly selected individuals aged 50-74 years in urban Adelaide were offered free fecal occult blood test screening by mail, without prior knowledge of their medical status. Each invitation included a questionnaire to record the prevalence of higher-than-average risk characteristics related to symptoms, family history or comorbidity, as well as prior colonoscopy. The definition of average risk was taken from updated guidelines published by the US Multisociety Task Force on Colorectal Cancer.
RESULTS: Of 2538 responses analyzed, 425 individuals had had a colonoscopy within the last 5 years, 106 fulfilled family history criteria for an initial screening colonoscopy, 209 had past polyps and 26 had had colorectal cancer. Eighty-three reported recent rectal bleeding. By current guidelines, 23% of the screened population did not warrant fecal occult blood test, because either prior colonoscopy rendered it unnecessary or particular patient characteristics made colonoscopy a more appropriate initial investigation.
CONCLUSIONS: Fecal occult blood test screening programs capture a sizeable number of higher-than-average risk individuals that may warrant colonoscopic rather than fecal occult blood test screening. Other participants have had a recent colonoscopy and probably warrant a delay in screening. Mass population fecal occult blood test-based screening programs need to more effectively target those at average risk and should divert those of higher or lower risk to more individualized assessment.

Entities:  

Mesh:

Year:  2006        PMID: 16957514     DOI: 10.1097/01.meg.0000231754.35340.fa

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  5 in total

Review 1.  Mannose-binding lectin and maladies of the bowel and liver.

Authors:  Daniel-L Worthley; Peter-G Bardy; David-L Gordon; Charles-G Mullighan
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

2.  Potential contribution of aspirin to cancer control programmes.

Authors:  G Morgan
Journal:  Ecancermedicalscience       Date:  2008-11-12

3.  Validation of an online questionnaire for identifying people at risk of familial and hereditary colorectal cancer.

Authors:  F G J Kallenberg; J E G IJspeert; P M M Bossuyt; C M Aalfs; E Dekker
Journal:  Fam Cancer       Date:  2015-09       Impact factor: 2.375

4.  Delayed Colonoscopy Following a Positive Fecal Test Result and Cancer Mortality.

Authors:  Anath A Flugelman; Nili Stein; Ori Segol; Idit Lavi; Lital Keinan-Boker
Journal:  JNCI Cancer Spectr       Date:  2019-05-02

5.  Identification of familial colorectal cancer and hereditary colorectal cancer syndromes through the Dutch population-screening program: results ofa pilot study.

Authors:  Sanne J H van Erp; Laura W Leicher; Simone D Hennink; Zeinab Ghorbanoghli; Simone A C Breg; Hans Morreau; Maartje Nielsen; James C H Hardwick; Jan A Roukema; Alexandra M J Langers; Wouter H de Vos Tot Nederveen Cappel; Hans F A Vasen
Journal:  Scand J Gastroenterol       Date:  2016-06-16       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.